Literature DB >> 1973161

Immunohistochemical study on overexpression of c-erbB-2 protein in human breast cancer: its correlation with gene amplification and long-term survival of patients.

H Tsuda1, S Hirohashi, Y Shimosato, Y Tanaka, T Hirota, S Tsugane, M Shiraishi, K Toyoshima, T Yamamoto, M Terada.   

Abstract

Using a polyclonal antibody monospecific to the c-erbB-2 oncogene product, an immunohistochemical study on the expression of c-erbB-2 protein was performed in formalin-fixed, paraffin-embedded tissue sections from 176 primary breast carcinomas in which amplification of the c-erbB-2 gene had been detected in 28 cases. Expression of the c-erbB-2 protein was detected in 44 cases (25%), being strongly positive in 27 (15%) and weakly positive in 17 (10%). All cases with amplification of c-erbB-2 showed positive staining of its protein. There were only four cases in which c-erbB-2 was strongly expressed without amplification of the gene. In the group showing strongly positive staining, both overall and disease-free survival were significantly poorer than in the remainder of the cases. Using Cox's regression model analysis, overexpression of c-erbB-2 protein was demonstrated to be an effective prognostic factor independent of nodal status or tumor size.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1973161      PMCID: PMC5918040          DOI: 10.1111/j.1349-7006.1990.tb02571.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  19 in total

1.  Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer.

Authors:  M J van de Vijver; J L Peterse; W J Mooi; P Wisman; J Lomans; O Dalesio; R Nusse
Journal:  N Engl J Med       Date:  1988-11-10       Impact factor: 91.245

2.  The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity.

Authors:  T Akiyama; C Sudo; H Ogawara; K Toyoshima; T Yamamoto
Journal:  Science       Date:  1986-06-27       Impact factor: 47.728

3.  Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures.

Authors:  S M Hsu; L Raine; H Fanger
Journal:  J Histochem Cytochem       Date:  1981-04       Impact factor: 2.479

4.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.

Authors:  D J Slamon; W Godolphin; L A Jones; J A Holt; S G Wong; D E Keith; W J Levin; S G Stuart; J Udove; A Ullrich
Journal:  Science       Date:  1989-05-12       Impact factor: 47.728

5.  Correlation between long-term survival in breast cancer patients and amplification of two putative oncogene-coamplification units: hst-1/int-2 and c-erbB-2/ear-1.

Authors:  H Tsuda; S Hirohashi; Y Shimosato; T Hirota; S Tsugane; H Yamamoto; N Miyajima; K Toyoshima; T Yamamoto; J Yokota
Journal:  Cancer Res       Date:  1989-06-01       Impact factor: 12.701

6.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.

Authors:  D J Slamon; G M Clark; S G Wong; W J Levin; A Ullrich; W L McGuire
Journal:  Science       Date:  1987-01-09       Impact factor: 47.728

7.  The neu gene: an erbB-homologous gene distinct from and unlinked to the gene encoding the EGF receptor.

Authors:  A L Schechter; M C Hung; L Vaidyanathan; R A Weinberg; T L Yang-Feng; U Francke; A Ullrich; L Coussens
Journal:  Science       Date:  1985-09-06       Impact factor: 47.728

8.  c-erbB-2 expression in benign and malignant breast disease.

Authors:  B A Gusterson; L G Machin; W J Gullick; N M Gibbs; T J Powles; C Elliott; S Ashley; P Monaghan; S Harrison
Journal:  Br J Cancer       Date:  1988-10       Impact factor: 7.640

9.  Association of elevated expression of the c-erbB-2 protein with spread of breast cancer.

Authors:  Y Yamada; M Yoshimoto; Y Murayama; M Ebuchi; S Mori; T Yamamoto; H Sugano; K Toyoshima
Journal:  Jpn J Cancer Res       Date:  1989-12

10.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples.

Authors:  R Peto; M C Pike; P Armitage; N E Breslow; D R Cox; S V Howard; N Mantel; K McPherson; J Peto; P G Smith
Journal:  Br J Cancer       Date:  1977-01       Impact factor: 7.640

View more
  14 in total

1.  Correlation between the Concentration of c-erbB-2 Protein, EGF-receptor and TGF alpha in Breast Cancer Tissue, and Clinicopathological Parameters.

Authors: 
Journal:  Breast Cancer       Date:  1994-07-30       Impact factor: 4.239

2.  Bilateral Breast Cancer in a Patient with a Strong Family History of Cancer: Analysis of p53 Germ Line Mutations.

Authors: 
Journal:  Breast Cancer       Date:  1994-12-30       Impact factor: 4.239

3.  Determination of ErbB2 protein in breast cancer tissues by different methods. Relationships with other biological parameters.

Authors:  A Piffanelli; R Dittadi; L Catozzi; M Gion; G Capitanio; M C Gelli; A Brazzale; R Malagutti; D Pelizzola; A Menegon; G Giovannini; G Gardini
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

4.  C-erbB-2 protein in the sera of breast cancer patients.

Authors:  T Narita; H Funahashi; Y Satoh; H Takagi
Journal:  Breast Cancer Res Treat       Date:  1992       Impact factor: 4.872

5.  The correlations between HPV16 infection and expressions of c-erbB-2 and bcl-2 in breast carcinoma.

Authors:  Qian He; Shu-Qun Zhang; Yong-Lie Chu; Xiao-Li Jia; Xiang-Ling Wang
Journal:  Mol Biol Rep       Date:  2008-04-22       Impact factor: 2.316

6.  Drug resistance as a dynamic process in a model for multistep gene amplification under various levels of selection stringency.

Authors:  L E Harnevo; Z Agur
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

7.  Investigation of soluble HER2 and transforming growth factor Beta-1 serum levels in gestational trophoblastic disease.

Authors:  Alamtaj Samsami Dehaghani; Neda Rahimi Rad; Mohammad Javad Fattahi; Baharak Khadang; Mohammad Amin Kashef; Zahra Sarraf; Abbas Ghaderi
Journal:  Pathol Oncol Res       Date:  2008-10-31       Impact factor: 3.201

8.  A clinicopathological analysis of breast cancer in patients with a family history.

Authors:  T Fukutomi; Y Kobayashi; T Nanasawa; H Yamamoto; H Tsuda
Journal:  Surg Today       Date:  1993       Impact factor: 2.549

9.  Squamoid features and expression of involucrin in primary breast carcinoma associated with high histological grade, tumour cell necrosis and recurrence sites.

Authors:  H Tsuda; C Sakamaki; T Fukutomi; S Hirohashi
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

10.  C-myc, not HER-2/neu, can predict recurrence and mortality of patients with node-negative breast cancer.

Authors:  Claus M Schlotter; Ulf Vogt; Ulrich Bosse; Berthold Mersch; Katja Wassmann
Journal:  Breast Cancer Res       Date:  2003-01-13       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.